The survival advantage and long-term duration of effect seen after few weeks of treatment with nimotuzumab across different studies and localizations of cancer may be explained by their combined mechanism of action: the inhibition of EGFR signal transduction and tumor proliferation, and the capacity to induce ADCC-mediated tumor cell killing and adaptive immunity through tumor antigen-specific T cells [9]. This evidence concerns the gene EGFR and cancer.